fibrogen.com - רווח החברה לפני מסים, ריבית ופחת FGEN

FibroGen, Inc. (FGEN) generates revenue from Roxadustat sales in the US and China, although it is currently undergoing rigorous cost optimization to preserve liquidity. The company's EBITDA clearly demonstrates actual cash flow, where 0.00 characterizes this valuation parameter. The business focuses on the nephrology market, offering a convenient oral drug, Evren, for anemia patients in hemodialysis centers.

To minimize risks when building a position, it is essential to track real-time cash flow dynamics, eliminating the time lags associated with quarterly reporting. By analyzing the operating cash flow, an investor can discern the actual ability of FibroGen, Inc. (FGEN) to generate profit, which is critical for a company with a history of failed research and bankruptcy threats, allowing for the timely recognition of business stagnation or dangerous asset overbought conditions.